Christopher M Depner

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11180821/publications.pdf

Version: 2024-02-01

471509 677142 2,242 28 17 22 g-index citations h-index papers 29 29 29 4133 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Sleep and circadian disruption and the gut microbiome-possible links to dysregulated metabolism. Current Opinion in Endocrine and Metabolic Research, 2021, 17, 26-37.	1.4	16
2	Effects of ad libitum food intake, insufficient sleep and weekend recovery sleep on energy balance. Sleep, 2021, 44, .	1.1	7
3	Challenges and Opportunities for Applying Wearable Technology to Sleep. Sleep Medicine Clinics, 2021, 16, 607-618.	2.6	12
4	Bone turnover marker responses to sleep restriction and weekend recovery sleep. Bone, 2021, 152, 116096.	2.9	7
5	Wearable technologies for developing sleep and circadian biomarkers: a summary of workshop discussions. Sleep, 2020, 43, .	1.1	160
6	Developing preliminary blood metabolomics-based biomarkers of insufficient sleep in humans. Sleep, 2020, 43, .	1.1	21
7	Sleep in university students prior to and during COVID-19 Stay-at-Home orders. Current Biology, 2020, 30, R797-R798.	3.9	217
8	0107 Altered Metabolites In The Human Plasma Metabolome During Insufficient Sleep Are Associated With Reduced Insulin Sensitivity. Sleep, 2019, 42, A44-A44.	1.1	0
9	0110 Within-subject Consistency Of Increased Interleukin-6 Levels In Response To Combined Sleep Restriction And Circadian Misalignment In Humans. Sleep, 2019, 42, A45-A46.	1.1	O
10	Trait-like vulnerability of higher-order cognition and ability to maintain wakefulness during combined sleep restriction and circadian misalignment. Sleep, 2019, 42, .	1.1	12
11	0108 Insufficient Sleep Alters After-Dinner Consumption of High-Carbohydrate Snacks. Sleep, 2019, 42, A44-A45.	1.1	O
12	0041 Preliminary Identification and Validation of a Plasma Metabolome-Based Biomarker for Circadian Phase in Humans. Sleep, 2019, 42, A17-A17.	1.1	0
13	Ad libitum Weekend Recovery Sleep Fails to Prevent Metabolic Dysregulation during a Repeating Pattern of Insufficient Sleep and Weekend Recovery Sleep. Current Biology, 2019, 29, 957-967.e4.	3.9	135
14	Omega-3 polyunsaturated fatty acids as a treatment strategy for nonalcoholic fatty liver disease. , 2018, 181, 108-125.		94
15	Mistimed food intake and sleep alters 24-hour time-of-day patterns of the human plasma proteome. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E5390-E5399.	7.1	82
16	Circadian Entrainment to the Natural Light-Dark Cycle across Seasons and the Weekend. Current Biology, 2017, 27, 508-513.	3.9	200
17	Impact of dietary fat on the development of non-alcoholic fatty liver disease in Ldlr $<$ sup $>$ â 2 /â 2 sup>mice. Proceedings of the Nutrition Society, 2016, 75, 1-9.	1.0	36
18	Morning Circadian Misalignment during Short Sleep Duration Impacts Insulin Sensitivity. Current Biology, 2015, 25, 3004-3010.	3.9	129

#	Article	IF	CITATIONS
19	Docosahexaenoic acid attenuates Western diet-induced hepatic fibrosis in Ldlr mice by targeting the TGFÎ ² -Smad3 pathway. Journal of Lipid Research, 2015, 56, 1936-1946.	4.2	39
20	Potential for Dietary i‰-3 Fatty Acids to Prevent Nonalcoholic Fatty Liver Disease and Reduce the Risk of Primary Liver Cancer. Advances in Nutrition, 2015, 6, 694-702.	6.4	64
21	Metabolic Consequences of Sleep and Circadian Disorders. Current Diabetes Reports, 2014, 14, 507.	4.2	319
22	Fatty Acid–Regulated Transcription Factors in the Liver. Annual Review of Nutrition, 2013, 33, 249-269.	10.1	178
23	Docosahexaenoic Acid Attenuates Hepatic Inflammation, Oxidative Stress, and Fibrosis without Decreasing Hepatosteatosis in a Ldlr Mouse Model of Western Diet-Induced Nonalcoholic Steatohepatitis. Journal of Nutrition, 2013, 143, 315-323.	2.9	116
24	A Metabolomic Analysis of Omega-3 Fatty Acid-Mediated Attenuation of Western Diet-Induced Nonalcoholic Steatohepatitis in LDLR-/- Mice. PLoS ONE, 2013, 8, e83756.	2.5	47
25	Menhaden Oil Decreases High-Fat Diet–Induced Markers of Hepatic Damage, Steatosis, Inflammation, and Fibrosis in Obese Ldlrâ⁻'/â⁻' Mice. Journal of Nutrition, 2012, 142, 1495-1503.	2.9	39
26	Omega-3 fatty acid supplementation and cardiovascular disease. Journal of Lipid Research, 2012, 53, 2525-2545.	4.2	181
27	Effect of ï‰3 PUFA on diet induced nonâ€alcoholic fatty liver disease (NAFLD) development and progression in C57BL/6J mice. FASEB Journal, 2012, 26, .	0.5	0
28	Hepatic PUFA content impacts fatty liver in mouse models of obesity & diabetes. FASEB Journal, 2011, 25, 349.5.	0.5	0